PREPARATION AND DISTRIBUTION OF RESEARCH DRUG PRODUCTS
ID: 75N95024R00003Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIDABethesda, MD, 20892, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH (AN11)

Original Source

https://sam.gov/opp/f34d61b358c8403aa3e9e51f3c4a07c7/view
Timeline
    Description

    The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA), is seeking proposals for the "Preparation and Distribution of Research Drug Products" under solicitation number 75N95024R00003. The primary objective of this procurement is to acquire, analyze, create, and distribute a variety of drug compounds essential for drug abuse and addiction research, including controlled and uncontrolled substances, while ensuring compliance with DEA regulations. This contract, structured as an indefinite delivery, indefinite quantity (IDIQ) agreement for a five-year period, aims to enhance research capabilities in the field of drug abuse, with proposals due by November 15, 2024, at 1:00 PM (Eastern Time). Interested parties should contact Scott Duernberger at scott.duernberger@nih.gov or Josh Lazarus at josh.lazarus@nih.gov for further information.

    Files
    Title
    Posted
    Amendment 01.pdf
    The document is an amendment to solicitation 75N95024R00003, issued by the National Institute on Drug Abuse (NIDA). It primarily serves to respond to questions raised by potential offerors regarding proposal requirements. The amendment clarifies that the Technical Proposal is limited to 200 pages, excluding specific introductory and supplementary elements. The document also confirms that a certification for cost or pricing data is not necessary due to expected price competition and specifies that all mandatory qualification criteria must be met upon receipt of the Technical Proposals. A critical detail includes the requirement that offerors must demonstrate access to a DEA-approved secure storage facility for refrigeration of an inventory of around 300 stock items at the time of submission. The proposal due date remains unchanged, set for November 5, 2024. This document emphasizes transparency in the federal procurement process while ensuring compliance with regulatory requirements necessary for contract bidding.
    Amendment 02.pdf
    The document is an amendment to a solicitation by the National Institute on Drug Abuse (NIDA) regarding a Request for Proposals (RFP) referenced as 75N95024R00003. Its primary purpose is to correct the due date for proposals, which remains unchanged as November 15th, 2024, at 1:00 PM (Eastern Time). The amendment outlines the procedures for potential offerors to acknowledge receipt of this change and emphasizes that all other terms and conditions of the solicitation remain intact. It is critical for respondents to confirm their understanding of the amendment, either through their proposals or via separate communication. The document reiterates the need for timely acknowledgment to avoid any potential rejection of offers. Overall, this amendment serves to clarify administrative aspects of the RFP process while ensuring compliance with procurement protocols.
    Solicitation_75N95024R00003_F.pdf
    The National Institute on Drug Abuse (NIDA) has issued Request for Proposal (RFP) No. 75N95024R00003 for the "Preparation and Distribution of Research Drug Products". The RFP invites proposals from qualified businesses with a submission deadline of November 15, 2024. The resulting contract is expected to incorporate an indefinite delivery, indefinite quantity (IDIQ) structure for a five-year period, allowing for cost reimbursement and/or fixed-price task orders based on NIDA's programmatic needs. Key focuses of the project will be acquiring, analyzing, creating, regulating, and distributing a variety of drug compounds essential for drug abuse research. All offerors are required to maintain active registration in the System for Award Management (SAM) and adhere to federal acquisition regulations. Proposals must be submitted electronically according to the guidelines stated in the attached documentation. Essential reporting and compliance requirements are outlined, ensuring transparency and accountability throughout the contract period. The contract aims to bolster research capabilities addressing drug abuse and addiction through defined deliverables and adherence to protocols involving controlled substances.
    SSN_OTSB_Final.pdf
    The National Institute on Drug Abuse (NIDA) is seeking Capability Statements from Other Than Small Business (OTSB) organizations for the preparation and distribution of research drug products in response to solicitation No. 75N95024R00003, focusing on controlled and uncontrolled drug compounds. This notice aims to assess the availability and capability of potential vendors while gathering information on their qualifications related to the NAICS code 541715. Interested parties must submit relevant documentation by November 16, 2023, specifying their compliance with mandatory requirements and project tasks outlined in the notice.
    Similar Opportunities
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Chemistry, Manufacturing, and Control (CMC) services related to the development of drug substances under RFP number 75N95024R00094. The primary objective is to secure high-quality drug substances to support preclinical and Investigational New Drug (IND)-enabling studies, ensuring compliance with current Good Manufacturing Practices (cGMP) and federal regulations. This initiative is crucial for advancing therapeutic innovations and facilitating collaborations in drug development, with a total funding amount of up to $49.7 million over the contract period from September 1, 2025, to May 14, 2031. Interested parties must submit their proposals by December 3, 2024, and can direct inquiries to primary contact Samson Shifaraw at samson.shifaraw@nih.gov or secondary contact Valerie Whipple at valerie.whipple@nih.gov.
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    A--NIH NeuroBioBank Brain and Tissue Repository
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for the establishment of the NIH NeuroBioBank Brain and Tissue Repository. The objective of this procurement is to create and manage contract collection sites for acquiring, storing, and distributing human brain and central nervous system tissues for research purposes, aimed at advancing the understanding of nervous system disorders. This initiative is critical for enhancing biomedical research by providing well-characterized specimens to researchers, thereby facilitating studies that could lead to improved treatments and interventions. Proposals are due by November 25, 2024, with the anticipated contract performance period starting on May 1, 2025, and extending potentially through multiple option years. Interested vendors should contact Robin D. Knightly at robin.knightly@nih.gov or call +1 301 827 5302 for further information.
    Scientific Management and Support to the National Institute of Mental Health (NIMH) Repository and Genomics Resource (NRGR)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for scientific management and support services for the National Institute of Mental Health Repository and Genomics Resource (NRGR). The objective of this procurement is to sustain, enhance, and enrich the NRGR, which provides critical biospecimens and genomic data for research on psychiatric disorders, thereby facilitating a deeper understanding of the genetic factors involved in mental health. This initiative is vital for advancing both basic and translational research in the field of mental health, ensuring broad access to valuable resources for researchers. Proposals are due by November 21, 2024, and must be submitted electronically via the NIH's eCPS system; interested parties can contact Sarah Adan at sarah.adan@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    Reagent Generation for Bioanalytical Method Development on Biologics
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified sources for a potential contract focused on reagent generation for bioanalytical method development related to biologics. The primary objective is to obtain information on the availability and capability of companies to generate and deliver reagents, including anti-drug antibodies, that support the quantification of novel biologic drugs in various biological matrices. This initiative is crucial for advancing drug development processes and improving success rates in preclinical stages, with the Therapeutic Development Branch (TDB) at NIH playing a pivotal role in moving therapeutic candidates through the drug development pipeline. Interested parties must submit their capability statements by November 8, 2024, to Nick Niefeld at nick.niefeld@nih.gov, referencing sources sought notice number 75N95025R00007.
    T--Managing,Editing,Publication of Alcohol Research
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute on Alcohol Abuse and Alcoholism (NIAAA), is preparing to issue a Request for Proposal (RFP) for the management, editing, and publication services of the journal "Alcohol Research: Current Reviews" (ARCR). The procurement aims to enhance the publication process of this peer-reviewed journal, which focuses on various alcohol research topics, including health impacts and treatment strategies. This contract, identified under Solicitation Number 75N94024Q00077, is expected to require approximately 8,211 hours of service in the base year, with an additional 32,844 hours across four option periods, totaling a maximum duration of 60 months. Interested organizations should note that the RFP is anticipated to be publicly available around November 14, 2024, with proposals due by December 16, 2024. For inquiries, contact Lisa Schaupp at lisa.schaupp@nih.gov or 301-827-8135.
    Clinical Site and Study Monitoring for NIMH Funded Research in Global Settings
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for clinical site and study monitoring services for research funded by the National Institute of Mental Health (NIMH) in global settings. The primary objective of this procurement is to support efforts aimed at reducing mental health disparities, particularly in low and middle-income countries, through rigorous monitoring practices that comply with federal regulations and Good Clinical Practice. This five-year contract, expected to commence on November 25, 2024, has an anticipated budget of up to $2,000,000, with firm-fixed price task orders awarded as needed. Interested parties should direct inquiries to Cassandra Conley at cassandra.conley@nih.gov or Rieka Plugge at rieka.plugge@nih.gov.
    HHS ONE PROFESSIONAL SERVICES SOLUTION (HOPSS)
    Active
    Health And Human Services, Department Of
    The U.S. Department of Health and Human Services (HHS), through the National Institute on Drug Abuse (NIDA), is hosting a virtual Market Research Industry Day for the HHS One Professional Services Solution (HOPSS). This initiative aims to gather industry feedback and inform potential contractors about the professional services required to support HHS's strategic goals for 2022-2026, which focus on enhancing healthcare access, improving health outcomes, promoting social equity, and advancing scientific research. The HOPSS contract will encompass two primary task areas: STEM services and business operational support, with the anticipated contract type being a multiple award Indefinite Delivery/Indefinite Quantity (IDIQ) contract set to begin around spring or summer 2026. Interested parties must register for the event by November 15, 2024, and direct any questions to Contract Specialist Kyle Miller at kyle.miller2@nih.gov by November 13, 2024.
    Notice of Intent to Sole Source; Monument Medical
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to QuVA Pharma, Inc. for the procurement of compounded intravenous (IV) narcotics for patient care at the NIH Clinical Center. This acquisition aims to secure sterile compounded products that meet the quality standards necessary for ongoing patient treatment, as QuVA Pharma is the sole distributor of these specific IV narcotics in the U.S. market. Interested parties are invited to express their interest and capabilities regarding this procurement, with comments due by November 15, 2024, at 10 AM EST, directed to Kristin Nagashima at kristin.nagashima@nih.gov.
    Consulting Services in relation to Medical Device Development under Blueprint MedTech Initiative – Subject Matter Expert in Medical Device Investment Development
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Institute on Drug Abuse (NIDA), intends to award a sole-source contract for consulting services related to medical device development under the Blueprint MedTech Initiative. The objective is to procure a subject matter expert with extensive experience in neurotechnology and mental health product development, who will provide strategic guidance and oversight for projects aimed at accelerating the translation of innovative medical devices for neurological disorders. This initiative, established in 2019 with a funding allocation of $32 million, seeks to facilitate the development of groundbreaking technologies and ensure their progression to clinical studies by 2027. Interested parties may submit their qualifications by November 8, 2024, to the designated contacts, Tracy Cain and Llakim Dubroff, at the NIH.